Works matching IS 11707690 AND DT 2020 AND VI 38 AND IP 1
Results: 11
Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.
- Published in:
- 2020
- By:
- Publication type:
- Letter
The New and Non-Transparent Cancer Drugs Fund.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
- Published in:
- 2020
- By:
- Publication type:
- corrected article
Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 1, p. 5, doi. 10.1007/s40273-019-00839-9
- By:
- Publication type:
- Article
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
- Published in:
- 2020
- By:
- Publication type:
- journal article